Company intelligence / Profile preview

Blue Bird Day

Somerville, Massachusetts, United Statesbluebirddayprogram.com ↗

Ownership: Private
Employees: ~248
Development stage: Commercial

Overview

bluebird bio has developed three FDA-approved, one-time ex-vivo lentiviral vector-based gene therapies for severe genetic diseases. ZYNTEGLO treats transfusion-dependent beta thalassemia; SKYSONA treats cerebral adrenoleukodystrophy; LYFGENIA treats sickle cell disease. Clinical data show durable responses with long-term follow-up in treated patients. The company withdrew from Europe due to reimbursement challenges but remains active commercially in the US.

Therapeutic areas: NeurologyHematology
Modalities: Gene therapyLentiviral vector gene therapyEx-vivo gene therapy
Industry: Biotech

Partnerships

Regeneron Pharmaceuticals (cell therapies for cancer)Bristol Myers Squibb/Celgene (CAR-T collaboration pre-oncology spinoff)

Beyond the preview

Go deeper on Blue Bird Day.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Bird Day.

Explore the full profile